Tag: AI Drug Discovery
Astromech scores $20M to predict biology’s next moves
The Colossal spin-off reaches a $3.8B valuation for AI that forecasts evolutionary change.
Blinded contest exposes uneven AI antibody design results
A blinded 29-team contest shows AI antibody tools can win in narrow tasks but fail at affinity prediction.
AI-discovered drugs still need a human name on the patent
US patent law still demands a human inventor even when AI did the creative work.
Chai Discovery scores BMS pact for AI-built antibodies
Chai Discovery adds Bristol Myers Squibb to its pharma roster for AI-built therapeutic antibodies.
Beyang banks $30M to push AI-designed eye and blood drugs
Chengdu-based Beyang Therapeutics closes an oversubscribed Series A to fund AI-designed retinal disease and leukemia candidates.
Aureka banks $100M Series B for biology foundation models
Aureka closes a $100M Series B to train biological foundation models for AI-driven drug discovery.
Pathos AI bets $125M on ADC its agent platform flagged
Pathos AI is paying $125M upfront for an Alphamab Oncology ADC that its Foundry agent platform flagged, plus a new…
Gates and Bezos back LifeMine’s $188M fungal drug revival
LifeMine is reviving its fungal genome platform with $188M from Bill Gates, Jeff Bezos and RA Capital, and will soon…